Thus, preventing the binding of PARP1 to DNA but not its enzymatic inhibition can be exploited for the therapeutic treatment of clinical cerebellar ataxias associated with unrepaired SSBs [109]. This evidence concerns the gene PARP1 and aceruloplasminemia.